Company announced preliminary Q4 2024 revenue
of approximately $34.9 million and FY 2024 revenue of approximately
$137.2 million, representing 12% year-over-year growth for the full
year
Quanterix Corporation (NASDAQ: QTRX), a company fueling
scientific discovery through ultrasensitive biomarker detection,
today announced selected preliminary, unaudited results for the
fourth quarter and full year ended December 31, 2024.
“I am pleased with our team’s execution as we delivered our
seventh consecutive quarter of double-digit revenue growth,” said
Masoud Toloue, PhD, President and Chief Executive Officer of
Quanterix. “Despite a difficult capital spending environment,
Quanterix has shown operational resiliency, and we expect to
continue to build on this performance, as we enter 2025 from a
position of strength. I am also excited about our recently
announced acquisition of Akoya Biosciences. We believe we can
create tremendous value by driving new growth and applying the same
robust execution to the combined company.”
Selected Preliminary, Unaudited Fourth
Quarter 2024 Financial Results
- Revenue of approximately $34.9 million for the three months
ended December 31, 2024, representing 11% year-over-year growth.
- Instruments revenue of approximately $3.1 million, representing
a 6% year-over-year decline.
- Consumables revenue of approximately $17.4 million, remaining
flat year-over-year.
- Accelerator revenue of approximately $8.6 million, representing
22% year-over-year growth. As previously disclosed, the fourth
quarter performance does not include $1.5 million of revenue from
an order under an agreement with Eli Lilly, which was completed in
the third quarter of 2024.
- Other revenue of approximately $5.8 million, representing 57%
year-over-year growth.
- The Company used approximately $4.4 million of cash in the
quarter ended December 31, 2024.
Selected Preliminary, Unaudited Full
Year 2024 Financial Results
- Revenue of approximately $137.2 million for the twelve months
ended December 31, 2024, representing 12% year-over-year growth.
- Instruments revenue of approximately $10.5 million,
representing a 33% year-over-year decline.
- Consumables revenue of approximately $69.3 million,
representing year-over-year growth of 8%.
- Accelerator revenue of approximately $38.0 million,
representing year-over-year growth of 36%.
- Other revenue of approximately $19.4 million, representing
year-over-year growth of 30%.
- The Company ended December 31, 2024 with cash, cash
equivalents, marketable securities and restricted cash of
approximately $292 million. The Company used approximately $32
million of cash in the twelve months ended December 31, 2024.
The Company’s unaudited, preliminary 2024 financial results are
based on current expectations and do not represent a comprehensive
statement of the Company’s financial results for the fourth quarter
or full year 2024. These unaudited, preliminary results remain
subject to the completion of financial closing procedures, internal
reviews, and annual audit procedures.
J.P. Morgan Healthcare
Conference
As previously announced, Quanterix’s President and Chief
Executive Officer Masoud Toloue will present at the 43rd Annual
J.P. Morgan Healthcare Conference taking place at the Westin St.
Francis Hotel in San Francisco, CA. Quanterix’s presentation will
be on Wednesday, January 15, 2025, at 4:30 p.m., PST. In addition
to the session, Quanterix will also host one-on-one meetings with
institutional investors during the conference. A live webcast of
the Company's presentation and question and answer session will be
available on the "Investors" section of the Company's website.
Earnings Call to Be Held on March 17,
2025
Quanterix also announced that it will release its fourth quarter
and full year 2024 financial results on Monday, March 17, 2025.
About Quanterix
From discovery to diagnostics, Quanterix’s ultrasensitive
biomarker detection is fueling breakthroughs only made possible
through its unparalleled sensitivity and flexibility. The Company’s
Simoa® technology has delivered the gold standard for earlier
biomarker detection in blood, serum or plasma, with the ability to
quantify proteins that are far lower than the Level of
Quantification (LoQ). Its industry-leading precision instruments,
digital immunoassay technology and CLIA-certified Accelerator
laboratory have supported research that advances disease
understanding and management in neurology, oncology, immunology,
cardiology and infectious disease. Quanterix has been a trusted
partner of the scientific community for nearly two decades,
powering research published in more than 3,100 peer-reviewed
journals. Find additional information about the Billerica,
Massachusetts-based company at https://www.quanterix.com or follow
us on Twitter and LinkedIn.
IMPORTANT ADDITIONAL INFORMATION
In connection with the proposed acquisition of Akoya
Biosciences, Inc. (“Akoya”) by Quanterix, Quanterix will file with
the U.S. Securities and Exchange Commission (the “SEC”) a
registration statement on Form S-4 (the “Registration Statement”),
which will contain a joint proxy statement of Quanterix and Akoya
and a prospectus of Quanterix (the “Joint Proxy
Statement/Prospectus”), and each of Quanterix and Akoya may file
with the SEC other relevant documents regarding the proposed
transaction. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE
REGISTRATION STATEMENT AND THE JOINT PROXY STATEMENT/PROSPECTUS
CAREFULLY AND IN THEIR ENTIRETY AND ANY OTHER RELEVANT DOCUMENTS
FILED WITH THE SEC BY QUANTERIX AND AKOYA, AS WELL AS ANY
AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS WHEN THEY BECOME
AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT
QUANTERIX, AKOYA AND THE PROPOSED TRANSACTION. A definitive copy of
the Joint Proxy Statement/Prospectus will be mailed to Quanterix
and Akoya stockholders when that document is final. Investors and
security holders will be able to obtain the Registration Statement
and the Joint Proxy Statement/Prospectus, as well as other filings
containing information about Quanterix and Akoya, free of charge
from Quanterix or Akoya or from the SEC’s website when they are
filed. The documents filed by Quanterix with the SEC may be
obtained free of charge at Quanterix’s website, at
www.quanterix.com, or by requesting them by mail at Quanterix
Investor Relations, 900 Middlesex Turnpike, Billerica, MA 01821.
The documents filed by Akoya with the SEC may be obtained free of
charge at Akoya’s website, at www.akoyabio.com, or by requesting
them by mail at Akoya Biosciences, Inc., 100 Campus Drive, 6th
Floor, Marlborough, MA 01752, ATTN: Chief Legal Officer.
PARTICIPANTS IN THE SOLICITATION
Quanterix and Akoya and certain of their respective directors
and executive officers may be deemed to be participants in the
solicitation of proxies from the stockholders of Quanterix or Akoya
in respect of the proposed transaction. Information about
Quanterix’s directors and executive officers is available in
Quanterix’s proxy statement dated April 15, 2024, for its 2024
Annual Meeting of Stockholders, and other documents filed by
Quanterix with the SEC. Information about Akoya’s directors and
executive officers is available in Akoya’s proxy statement dated
April 23, 2024, for its 2024 Annual Meeting of Stockholders, and
other documents filed by Akoya with the SEC. Other information
regarding the persons who may, under the rules of the SEC, be
deemed participants in the proxy solicitation and a description of
their direct and indirect interests, by security holdings or
otherwise, will be contained in the Joint Proxy
Statement/Prospectus and other relevant materials to be filed with
the SEC regarding the proposed transaction when they become
available. Investors should read the Joint Proxy
Statement/Prospectus carefully when it becomes available before
making any voting or investment decisions. You may obtain free
copies of these documents from Quanterix or Akoya as indicated
above.
NO OFFER OR SOLICITATION
This communication shall not constitute an offer to sell or the
solicitation of an offer to buy any securities or a solicitation of
any vote or approval with respect to the proposed merger of
Quanterix and Akoya, nor shall there be any sale of securities in
any jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such jurisdiction. No offering of securities
shall be made except by means of a prospectus meeting the
requirements of Section 10 of the U.S. Securities Act of 1933, as
amended.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING
STATEMENTS
The selected financial results for the fourth quarter and full
year ended December 31, 2024 included in this press release are
preliminary, unaudited and subject to completion. Such preliminary
results are subject to the finalization of quarter and year-end
financial and accounting procedures, and actual results may vary
from the preliminary results presented herein. The preliminary
results represent management estimates that constitute
forward-looking statements subject to risks and uncertainties.
Statements included in this communication that are not
historical in nature or do not relate to current facts are intended
to be, and are hereby identified as, forward-looking statements for
purposes of the safe harbor provided by Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Forward-looking
statements are based on, among other things, projections as to the
anticipated benefits of the proposed transaction as well as
statements regarding the impact of the proposed transaction on
Quanterix’s and Akoya’s business and future financial and operating
results, the amount and timing of synergies from the proposed
transaction and the closing date for the proposed transaction.
Words and phrases such as “may,” “approximately,” “continue,”
“should,” “expects,” “projects,” “anticipates,” “is likely,” “look
ahead,” “look forward,” “believes,” “will,” “intends,” “estimates,”
“strategy,” “plan,” “could,” “potential,” “possible,” and
variations of such words and similar expressions are intended to
identify such forward-looking statements. Quanterix and Akoya
caution readers that forward-looking statements are subject to
certain risks and uncertainties that are difficult to predict with
regard to, among other things, timing, extent, likelihood, and
degree of occurrence, which could cause actual results to differ
materially from anticipated results. Such risks and uncertainties
include, among others, the following possibilities with respect to
the transaction with Akoya: the occurrence of any event, change or
other circumstances that could give rise to the right of one or
both of the parties to terminate the definitive merger agreement
entered into between Quanterix and Akoya; the outcome of any legal
proceedings that may be instituted against Quanterix or Akoya; the
failure to obtain necessary regulatory approvals (and the risk that
such approvals may result in the imposition of conditions that
could adversely affect the combined company or the expected
benefits of the proposed transaction) and stockholder approvals or
to satisfy any of the other conditions to the proposed transaction
on a timely basis or at all; the possibility that the anticipated
benefits and synergies of the proposed transaction are not realized
when expected or at all, including as a result of the impact of, or
problems arising from, the integration of the two companies or as a
result of the strength of the economy and competitive factors in
the areas where Quanterix and Akoya do business; the possibility
that the proposed transaction may be more expensive to complete
than anticipated; diversion of management’s attention from ongoing
business operations and opportunities; potential adverse reactions
or changes to business or employee relationships, including those
resulting from the announcement or completion of the proposed
transaction; changes in Quanterix’s share price before the closing
of the proposed transaction; risks relating to the potential
dilutive effect of shares of Quanterix common stock to be issued in
the proposed transaction; and other factors that may affect future
results of Quanterix, Akoya and the combined company. Additional
factors that could cause results to differ materially from those
described above can be found in Quanterix’s Annual Report on Form
10-K for the year ended December 31, 2023, as amended, Akoya’s
Annual Report on Form 10-K for the year ended December 31, 2023,
and in other documents Quanterix and Akoya file with the SEC, which
are available on the SEC’s website at www.sec.gov.
All forward-looking statements, expressed or implied, included
in this communication are expressly qualified in their entirety by
the cautionary statements contained or referred to herein. If one
or more events related to these or other risks or uncertainties
materialize, or if Quanterix’s or Akoya’s underlying assumptions
prove to be incorrect, actual results may differ materially from
what Quanterix and Akoya anticipate. Quanterix and Akoya caution
readers not to place undue reliance on any such forward-looking
statements, which speak only as of the date they are made and are
based on information available at that time. Neither Quanterix nor
Akoya assumes any obligation to update or otherwise revise any
forward-looking statements to reflect circumstances or events that
occur after the date the forward-looking statements were made or to
reflect the occurrence of unanticipated events except as required
by federal securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250114115283/en/
Quanterix Contacts
Media Contact: Marissa Klaassen
media@quanterix.com
Investor Relations Contact: Joshua Young
ir@quanterix.com
Quanterix (NASDAQ:QTRX)
過去 株価チャート
から 12 2024 まで 1 2025
Quanterix (NASDAQ:QTRX)
過去 株価チャート
から 1 2024 まで 1 2025
